Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874714 | 1.00 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL5493410 | 0.92 | NR4A2 (0.43) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL29828567 | 0.88 | NR4A2 (0.50) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL152998 | 0.88 | NR4A2 (0.50) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL16056048 | 0.87 | NR4A2 (0.47) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL30752924 | 0.86 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL7662781 | 0.86 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL275285 | 0.86 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL7865843 | 0.85 | NR4A2 (0.48) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL31434284 | 0.85 | NR4A2 (0.48) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096651-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4692092-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | Aliad Biopharma (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528825-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2005100351-A1 | NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005073205-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20040058970-A1 | Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-0409406-B1 | ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-08 | — | — | EP | disclosed |
| EP-0487502-A2 | Pharmaceutically active aryl-substituted amine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-27 | — | — | EP | disclosed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | disclosed |
| EP-0069810-B1 | NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS | MERCK & CO. INC. (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4282365-A | Dibenz[b,e]oxepin compounds | MERCK & CO., INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | NR4A2 559/4885ALDH1A1 2698/4885GAA 3421/4885 |
| US-20040058970-A1 | Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands | GABRA5, GABRA1, GABRB1 | NR4A2 207/4885ALDH1A1 717/4885GAA 1559/4885 |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | NR4A2 2412/4885ALDH1A1 4614/4885GAA 1494/4885 |
| US-12528825-B2 | Compounds and uses thereof | BRD9, BRD8, BRIX1 | NR4A2 1577/4885ALDH1A1 4477/4885GAA 2491/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | NR4A2 736/4885ALDH1A1 4143/4885GAA 2456/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | NR4A2 2922/4885ALDH1A1 4621/4885GAA 1183/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | NR4A2 2771/4885ALDH1A1 4714/4885GAA 1572/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | NR4A2 217/4885ALDH1A1 100/4885GAA 2519/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | NR4A2 2721/4885ALDH1A1 2777/4885GAA 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.